It would seem there should be at least news of new patients or DSMB approvals since the last patient injections. I wonder what's up.
Since Gary claims multiple company titles, things at the top probably get delayed and bottlenecked. To boot, It's not a stretch to think Gary has somewhat of a conflict of interest in hiring away responsibilities, since it allows him to award himself more shares.
Finally, I think Gary has somewhat misled investors to think the trials will continue on an increased pace, when it appears things have slowed down.
I'm not too pleased with the last few months progress. Over a year in, one would expect a little efficiency with the trials.
It's really not all that strange , when you see Gary making a presentation at the Waldorf Astoria in NYC, to an audience of investors he said was impossible to convince to buy shares of ACTC, then get only one question asked at the end. Now thats a leader we can all be proud of, right?